Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/Ⅱ Clinical Study to Explore the Effectiveness and Safety of Camrelizumab/Lenvatinib Combined With TACE in Patients With Borderline Resectable Hepatocellular Carcinoma

NCT05042336 is registered in ClinicalTrials.gov with Sichuan University as lead sponsor.

NCT NCT05042336
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05042336 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/Ⅱ Clinical Study to Explore the Effectiveness and Safety of Camrelizumab/Lenvatinib Combined With TACE in Patients With Borderline Resectable Hepatocellular Carcinoma
Lead sponsor
Sichuan University
Phase
Phase 1/2
Overall status
Unknown status
Start date
September 1, 2021
Completion date
October 1, 2023
Enrollment
49 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

borderline resectable hepatocellular carcinoma, carrelizumab plus lenvatinib combined with tace